<PAGE> 1
FORM 10-Q/A
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1998
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
------- --------
Commission file number: 0-12042
BIOGEN, INC.
(Exact name of Registrant as specified in its charter)
Massachusetts 04-3002117
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
14 Cambridge Center, Cambridge, Massachusetts 02142
(Address of principal executive offices)(zip code)
Registrant's telephone number, including area code: (617) 679-2000
Former name, former address and former fiscal year, if changed since
last report: Not Applicable
Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
Yes [X] No [ ]
Number of shares outstanding of each of the issuer's classes of Common Stock, as
of August 12, 1998:
COMMON STOCK, PAR VALUE $0.01 73,732,655
- ----------------------------- ----------
(Title of each class) (Number of shares)
<PAGE> 2
This purpose of this amendment is to re-file Exhibit 10.1.1 to the Form
10-Q without redaction of certain language for which the Registrant did not
receive confidential treatment.
<PAGE> 3
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
BIOGEN, INC.
By: /s/ Michael J. Astrue
--------------------------------
Vice President - General Counsel
Dated June 4, 1999
<PAGE> 4
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
(10.1.1) Agreement and Amendment between the Company and Schering
Corporation dated May 1, 1998* (filed herewith)
(10.1.2) 1985 Non-qualified Stock Option Plan, as amended through June 20,
1998 and restated **
(10.1.3) 1982 Incentive Stock Option Plan, as amended through June 20,
1998 and restated**
*Confidential Treatment requested as to certain portions, which portions are
omitted and filed separately with the Securities and Exchange Commission.
**Previously filed as an exhibit to the Registrant's Quarterly Report on Form
10-Q for the quarter ended June 30, 1998.
<PAGE> 1
Exhibit 10.1.1
Biogen, Inc. has omitted from this Exhibit 10.1.1 portions of the Agreement
for which Biogen, Inc. has requested confidential treatment from the Securities
and Exchange Commission. The portions of the Agreement for which confidential
treatment has been requested are marked with X's in brackets and such
confidential portions have been filed separately with the Securities and
Exchange Commission.
AGREEMENT AND AMENDMENT
This Agreement and Amendment (this "Biogen Amendment") is made as of this
1st day of May, 1998, by and between Biogen, Inc., a corporation organized under
the laws of the Commonwealth of Massachusetts and having its principal place of
business at 14 Cambridge Center, Cambridge, Massachusetts 02142 ("Biogen"), and
Schering Corporation, a corporation organized under the laws of the State of New
Jersey and having its principal place of business at 2000 Galloping Hill Road,
Kenilworth, New Jersey 07033 ("Schering").
WITNESSETH:
WHEREAS, Schering and Biogen, as successor to Biogen N.V., a corporation
organized under the laws of the Netherlands Antilles, are parties to an
Exclusive License and Development Agreement, dated December 8, 1979, relating to
human recombinant leukocyte interferon (such agreement, as amended to date by
the Prior Amendments as defined below, the "Biogen-Schering Agreement"); and
WHEREAS, certain patent rights owned or controlled by Schering and Biogen,
on the one hand, and by Hoffmann-La Roche, Inc. ("Roche") and Genentech, Inc.
("Genentech"), on the other hand, covering the use, manufacture and sale of the
respective interferon alpha products of Schering and Roche have been in dispute
as among Biogen, Schering, Roche and Genentech and have been the subject of an
interference proceeding before -the Board of Patent Appeals and Interferences of
the United States Patent and Trademark Office ("USPTO"), entitled DAVID V.
GOEDDEL AND SIDNEY PESTKA v. Charles WEISSMANN, Interference No. 101,601 (the
"Interference"), which awarded priority to the Goeddel and Pestka Application
(the "Roche/Genentech Patent Application") over the Weissmann Application in the
Interference. This Interference decision has been appealed ('Interference
Appeal") to the United States District Court for the District of Massachusetts
(the "Court"); and
WHEREAS, all the parties wish to avoid the risk and expense attendant upon
further litigation and to settle all claims which have been brought in the
Interference Appeal, and in order to accomplish these objectives, the parties
wish to enter into a settlement agreement as of the same date hereof which
specifies
<PAGE> 2
the terms and conditions agreed to by the parties to resolve the Interference
Appeal (the "Settlement Agreement"); and
WHEREAS, in connection with the Settlement Agreement, Schering, Biogen,
Genentech and Roche (where applicable) have agreed to execute this Biogen
Amendment and the Fourth Amendment to that certain agreement dated May 14, 1985
by and between Schering and Roche relating to recombinant human leukocyte
interferon (such agreement, as amended by prior amendments thereto, dated May
14, 1985, August 27, 1986, and October 9, 1986, the "Roche-Schering Agreement")
(the "Fourth Amendment," and the Biogen Amendment and the Fourth Amendment
together, the "Amendments"); and
WHEREAS, Schering and Biogen agree to the assignment of the Weissmann
Application to Schering upon the receipt of all required governmental consents
and approvals and the observance of all applicable waiting periods under the
Hart-Scott-Rodino Antitrust Improvements Act ("HSR Act") in connection with the
Biogen Amendment, the Fourth Amendment and the Settlement Agreement (the
"Governmental Approvals"); and
WHEREAS, Schering recognizes that (i) royalty payments might have been due
to Biogen under the Biogen Agreement if the Weissmann Application prevailed and
(ii) the payments to be made hereunder are made in consideration of the
assignment to Schering of the Weissmann Application and the grant to Schering of
the rights set forth in Section 3.2.
NOW, THEREFORE, in consideration of the mutual covenants and agreements
contained herein, the parties hereto, intending to be legally bound, do hereby
agree as follows:
1. DEFINITIONS.
1.1. All capitalized terms used herein and not otherwise defined shall have
the respective earnings set forth in the Biogen-Schering Agreement.
1.2. "Additional Patent Rights" shall mean any United States patents that
shall issue to Biogen from the following patent applications or any divisional,
continuation, continuation-in-part, continuing prosecution application, reissue,
renewal or extension thereof or substitute therefor:[xxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxx]; however, U.S. Serial No. 471, 30 1, filed March 3, 1983
is excluded from this definition.
-2-
<PAGE> 3
1.3. "Biogen Patent" shall mean U.S. Patent No. 4,530,901 entitled
"Recombinant DNA Molecules and Their Use in Producing Interferon-Like
Polypeptides," issued on July 23, 1985.
1.4. "Prior Amendments" shall mean the amendments and supplements to the
Exclusive License and Development Agreement dated as of December 8, 1979, by and
between Biogen, Biogen .V., and Biogen N.V. and Schering, executed prior to the
date hereof, including without limitation the following: (i) Supplemental
Agreement, dated as of March 11, 1983, by and between Biogen N.V., Biogen B.V.
and Schering; (ii) Amendatory Agreement, dated as of May 14, 1985, by and
between Biogen B.V. and Schering; (iii) Amendment and Settlement Agreement,
dated as of September 29, 1988 by and between Biogen, Biogen B.V. and Schering;
(iv) Amendment, dated as of March 20, 1989 by and between Biogen B.V. and
Schering; (v) Amendment, dated as of March 23, 1992, by and between Biogen and
Schering; and (vi) Supplemental Amendment and Agreement, dated as of March 1,
1994, by and between Schering and Biogen.
1.5. "Roche Patent Rights" shall mean any United States patents that shall
issue from patent applications owned or controlled by Roche individually or
jointly with Genentech, that were the subject of the Interference, including,
but not limited to,[xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx xxxxxxxxxx] or from
any divisional, continuation, continuation-in-part, continuing prosecution
application, reissue or extension thereof or substitute therefor.
1.6. "Royalty Termination Date" shall mean (as applicable):
a) with respect to Additional Patent Rights for any given Licensed Product
or Licensed Combination Product, the last to expire of any issued Additional
Patent Rights which has a claim that covers the manufacture, use, offer to sell,
sale, export or import of such Licensed Product or Licensed Combinations Product
(both as defined in the Biogen-Schering Agreement); or
b) with respect to the Roche Patent Rights, for any given Licensed SCHERING
Product the last to expire of any issued Roche Patent Rights which has a claim
that covers the manufacture, use, sale, offer to sell, export or import of such
Licensed SCHERING Products, as defined by the Roche-Schering Agreement, as
amended by the Fourth Amendment.
1.7. "Weissmann Application" shall mean U.S. Serial No. 471,301 filed March
2, 1983.
2. ROCHE PATENT RIGHTS. Biogen hereby acknowledges that Schering is
entering into the Fourth Amendment with Roche under
-3-
<PAGE> 4
which Roche has agreed to grant Schering an exclusive (even as to Roche),
non-transferable license and an immunity from suit under the Roche and
Roche/Genentech Patent Rights for use solely within the United States to
manufacture, have manufactured, import, export, use, offer to sell, and sell
Licensed SCHERING Products (as such terms are defined by the Roche-Schering
Agreement, as amended by the Fourth Amendment). Biogen also acknowledges that,
for consideration granted herein, it retains no right, title or interest in the
rights granted to Schering by Roche in the Roche-Schering Agreement, as amended
by the Fourth Amendment.
3. ASSIGNMENT OF WEISSMANN APPLICATION.
3.l. Biogen hereby agrees to assign, transfer and convey to Schering all of
its right, title and interest in and to the Weissmann Application by executing
and delivering, within ten (10) days of the last to occur of the Governmental
Approvals, an Assignment of Patent Rights substantially in the form of Exhibit A
attached hereto (the "Patent Assignment"). Biogen further covenants and agrees
that it will from time to time, if requested by Schering, execute, acknowledge
and deliver such additional documents and instruments as may be reasonably
necessary to effectuate the foregoing assignment.
3.2. Biogen also agrees that it will assign to Schering, as assignee of the
Weissmann Application, contemporaneously with the assignment of the Weissmann
Application, the right (i) to contest or consent to the decision of the Board of
Patent Appeals and Interferences of the USPTO rendered on December 15, 1995 in
the Interference and (ii) to take such actions as Schering in its sole
discretion may determine in order to carry on or to conclude the Interference
and the Interference Appeal.
3.3. If, for any reason, the Court does not approve, or withdraws its
approval of, the Settlement Agreement, or the Settlement Agreement is declared
null and void ab initio after the assignments contemplated in paragraphs 3.1 and
3.2 herein occur, then such assignments shall be deemed null and void ab initio
and have no further force and effect and Schering shall execute, acknowledge and
deliver such documents and instruments as may be reasonably necessary to
effectuate the reassignment to Biogen of all rights assigned pursuant to
Sections 3.1 and 3.2 herein.
4. COVENANTS OF SCHERING.
4.1. Schering hereby covenants and agrees that it shall (i) seek to enforce
in a commercially reasonable matter Article 11 of the Fourth Amendment; (ii)
keep Biogen informed in
-4-
<PAGE> 5
a reasonably prompt manner of all substantive actions of which Schering is aware
have been taken with respect to the Roche Patent Rights; and (iii) provide
Biogen with copies of all substantive filings and substantive correspondence, to
the extent permissible under law, with respect to the Roche Patent Rights that
Schering receives from Roche or any governmental authority.
4.2. Schering hereby represents and warrants that, other than with respect
to certain confidential financial terms which have been deleted, the copy of the
Roche-Schering Agreement provided to Biogen on the date hereof is true and
correct.
5. AMENDMENTS TO THE BIOGEN-SCHERING AGREEMENT.
5.1. Section 5.1 of the Biogen-Schering Agreement is hereby amended by
deleting the second sentence (i.e., the first full sentence) beginning on page
29 of the Biogen-Schering Agreement, as amended by the Prior Amendments, and
substituting in lieu thereof the following:
Such earned royalties shall be paid (i) at the rate of [xxxxxxxxxxxxxxxxx]
with respect to Licensed Products other than Licensed Combination Products
and [xx] times the "proration factor" with respect to Licensed Combination
Products [xxxxxxxxxxxxxxxxxxxxxxxxx] of aggregate Sales Value (including
aggregate Sales Value of Licensed Combination Products) of such sales
during each License Year and (ii) at the rate of [xxxxxxxxxxxxxxxxxxxxxxxxx
x] with respect to Licensed Products other than Licensed Combination
Products and [xxxxx]times the "proration factor" with respect to Licensed
Combination Products on the aggregate Sales Value (including aggregate
Sales Value of Licensed Combination Products) of all such sales [xxxxxxxxxx
xxxxxxxx]in each License Year; provided that no royalties shall be paid
under any circumstances on Licensed Products or Licensed Combination
Products sold or manufactured in the United States following the date of
expiration of the Biogen Patent, i.e., July 23, 2002 (the "Patent
Expiration Date"); except that
(A) After the Patent Expiration Date and through the Royalty
Termination Date, in consideration of the assignments described in
Sections 3.1 and 3.2 above, royalties shall be paid (I) with respect
to Licensed Products sold in the United States during the periods
specified below other than Licensed Combination Products, at the
royalty rates specified below and (ii) with respect to Licensed
Combination Products sold in the United States during such periods at
the royalty rates specified below times the "proration factor"
-5-
<PAGE> 6
Royalty Rate
(Percent of
Royalty Period Sales Value)
-------------- ------------
After the Patent Expiration [x]
Date until July 22, 2003
On or after July 23, 2003 [xxx]
until July 22, 2004
On or after July 23, 2004 [x]
until July 22, 2005
On or after July 23, 2005 [xxx]
until July 22, 2006
On or after July 23, 2006 [x]
until July 22, 2007
On or after July 23, 2007 and [xxx]
until the Royalty Termination
Date
; and
(B) After the Patent Expiration Date, with respect to Licensed
Products and Licensed Combination Products manufactured in the United
States and sold outside the United States, royalties shall be paid if
and only to the extent that Biogen still owns an unexpired patent or
supplementary protection certificate covering such Licensed Products
or Licensed Combination Products in the country in which such Licensed
Products or Licensed Combination Products are sold. Any such royalties
shall be paid (i) at the rate of [xxxx xxxxxxxxxxxx] with respect to
Licensed Products other than Licensed Combination Products and [xx]
times the "proration factor" with respect to Licensed Combination
Products on such sales [xxxxxxxxxxxxxxxx xxxxxxxx] of aggregate Sales
Value (including aggregate Sales Value of Licensed Combination
Products) of sales during each License Year; and (ii) at the rate of
[xxxxxxxxxxxxxxxxxxxxxx] with respect to Licensed Products and [xxxxx]
times the "proration factor" with respect to Licensed Combination
Products on such sales within the aggregate Sales Value (including
aggregate Sales Value of Licensed Combination Products) of all sales
[xxxxxxxxxxxxxx xxxxx]in each License Year.
-6-
<PAGE> 7
For purposes of the foregoing subsections (A) and (B), the Roche Patent
Rights shall be deemed to be a "patent with respect to any Biogen
Invention" under Section 1. 14(a)(i) of this Schering-Biogen Agreement.
5.2 As further consideration for the execution by Schering of this Biogen
Amendment, Biogen hereby agrees that Schering shall be entitled to deduct from
earned royalties due under the Biogen-Schering Agreement with respect to
Licensed Products sold during any calendar year from and after the calendar year
[xxxx] under the Roche-Schering Agreement up to [xxxxxxx] per calendar year,
which deductions shall be made from the royalty payment for the third quarter of
the License Year in question until a maximum of [xxxxxxxx] has been deducted. It
is intended by the parties that no royalties paid by Schering to Roche shall be
deductible from royalties due to Biogen under the Biogen-Schering Agreement or
hereunder, unless otherwise agreed to by the parties in writing.
6. CONSENTS AND APPROVALS; COOPERATION.
6.1. Schering and Biogen shall in good faith cooperate to obtain all
Governmental Approvals. Both parties agree to: (i) take promptly all actions
necessary to make the filings required of the parties; (ii) comply at the
earliest practicable date with any requests for additional information received
either by Biogen or Schering from a governmental authority; and (iii) furnish to
each other such information and assistance as may reasonably be requested in
connection with the foregoing, to the extent permissible under law. Biogen and
Schering agree to provide the other with copies of all correspondence between
either of them (or their advisors) and any government antitrust entity relating
to this Biogen Amendment, the Fourth Amendment or the Settlement Agreement to
the extent permissible under law. Biogen and Schering agree that all meetings
with a governmental authority relating to any matters described in this Section
6.1 shall include representatives of both Biogen and Schering unless Biogen and
Schering jointly decide otherwise or the governmental authority objects to such
attendance.
6.2. Nothing in this Biogen Amendment shall require Biogen or Schering, as
a consequence of any government action or threatened action, to change, modify,
add, or delete any material term in this Biogen Amendment, or to take any other
action that shall have a material adverse effect on such party. Either party may
provide notice to the other party that it concludes, in good faith, it would not
be feasible and consistent with the intentions of the parties in entering into
this Biogen Amendment to continue the effectiveness of this Biogen Amendment in
the event any governmental agency seeks to enjoin or a court enjoins the parties
from acting pursuant to this Biogen Amendment or a governmental authority seeks
to terminate this Biogen Amendment. Upon the receipt of such notice by the other
party, this Biogen Amendment shall be
-7-
<PAGE> 8
declared null and void ab initio and the Biogen-Schering Agreement shall remain
in full force and effect as if this Biogen Amendment and Patent Assignment had
never been executed, and Schering shall execute an assignment in mutually
satisfactory form assigning the Weissmann Application to Biogen.
7. CONFIDENTIALITY. No party shall make any public statements with respect
to this Biogen Amendment or the transactions or agreements contemplated hereby,
the Fourth Amendment, the Interference, the Interference Appeal, the Settlement
Agreement, nor shall any of the parties hereto disclose to any third party the
terms of this Biogen Amendment or any of the other agreements referenced in this
Section 7, or the relationships created hereby, without, in any such case, the
prior written consent of the other parties hereto, except as required by law or
regulation. Each party may make a press release concerning this Biogen Agreement
or the Settlement Agreement, but agree that prior to making such release, such
party will submit the text thereof to the other party and shall issue the
release only with the approval of such party, which approval shall not be
unreasonably withheld; provided, that, once information has been released in
accordance with this Section 7, the information contained in such release may
subsequently be released by the releasing party without the prior approval or
consent of the other party.
8. REVOCATION. In addition to those rights specified in Paragraph 6.2
above, this Biogen Amendment and the Patent Assignment (if executed), shall be
null and void ab initio, and Schering shall execute an assignment in mutually
satisfactory form assigning the Weissmann Application to Biogen and the present
Biogen-Schering Agreement (prior to this Biogen Amendment), shall remain in full
force and effect as if this Biogen Amendment and the Patent Assignment (if
executed) had never been executed, if (i) either a stay of litigation in the
Interference Appeal agreed to by the parties in the Settlement Agreement is not
granted by the court or is lifted by the court prior to the termination of the
Interference Appeal by Schering, as assignee of Biogen, under the provisions of
Paragraph 3 of the Settlement Agreement; (ii) the Settlement Agreement is
properly declared null and void ab initio or a governmental authority whose
prior approval must be obtained, enjoins, rejects or rescinds the Settlement
Agreement, the Fourth Amendment, or this Biogen Amendment or otherwise fails to
render a final approval on or before December 31, 1998; or (iii) Roche fails to
enter into the Fourth Amendment.
9. COVENANTS OF BIOGEN. Section 12.1 of the Biogen-Schering Agreement shall
apply to the prosecution of Additional Patent Rights. In addition, Biogen hereby
covenants and agrees that it shall (i) keep Schering fully informed of all
actions
-8-
<PAGE> 9
taken with respect to the Additional Patent Rights, and (ii) provide Schering
with copies of all proposed filings and correspondence with respect to the
Additional Patent Rights at least thirty (30) days before submission to the
relevant patent office, and give good faith consideration to any comments and
suggestions of Schering with respect thereto. Any and all costs and expenses
incurred by Biogen in connection with any such actions shall be borne by Biogen.
10. MISCELLANEOUS.
10.1. This Biogen Amendment shall constitute an amendment of the
Biogen-Schering Agreement within the meaning of Section 18 thereof.
10.2. Except as expressly set forth herein, all of the other terms and
conditions of the Biogen-Schering Agreement shall remain in full force and
effect.
10.3. In the event of any inconsistency between this Biogen Amendment and
the Biogen Agreement (as previously amended), the provisions of this Biogen
Amendment shall govern.
IN WITNESS WHEREOF, the parties have caused this Biogen Amendment to be
executed by their respective officers hereunto duly authorized as of the date
and year first written above.
SCHERING CORPORATION
By:
-------------------------------------
Name: Thomas C. Lauda
Title: Vice President
BIOGEN, INC.
By: -------------------------------------
Name: James R. Tobin
Title: President & Chief Executive Officer
-9-
<PAGE> 10
EXHIBIT A
ASSIGNMENT OF PATENT RIGHTS
ASSIGNMENT OF PATENT RIGHTS, dated as of May _, 1998 from Biogen, Inc., a
Massachusetts corporation ("Biogen"), to Schering Corporation, a New Jersey
corporation ("Schering").
WITNESSETH
WHEREAS, Biogen and Schering have entered into an Agreement and Amendment
dated as of even date hereof (the "Biogen Amendment"), pursuant to which Biogen
has agreed to transfer certain patent rights to Schering upon the receipt of
certain governmental approvals and consents and observance of certain waiting
periods specified therein ("Governmental Approvals") in exchange for the payment
by Schering of certain royalties specified therein.
NOW, THEREFORE, in consideration of the premises and in satisfaction of its
obligation under the Biogen Amendment and for other good and valuable
consideration, the receipt, adequacy and sufficiency of which is hereby
acknowledged, Biogen hereby conveys, transfers and assigns to, and vests in
Schering and its successors and assigns, all of Biogen's right, title and
interest, in and to the patent rights described on Schedule A attached hereto
(the "Assigned Patent Rights").
TO HAVE AND TO HOLD all of the foregoing Assigned Patent Rights unto
Schering, its successors and assigns, to its and their own proper use forever:
1. Biogen, for itself and its successors and assigns, hereby covenants
that, at any time and from time TO time after delivery of this instrument, at
Schering's request and expense but without further consideration, Biogen will
do, execute, acknowledge and deliver, or will cause to be done, executed,
acknowledged and delivered, all and every such further acts, conveyances,
instruments, transfers, assignments, powers of attorney and assurances as
reasonably may be required for the better assuring, conveying, transferring,
confirming and vesting in or to Schering, the Assigned Patent Rights or to
enable Schering, its successors and assigns, to realize upon or otherwise to
enjoy the Assigned Patent Rights.
2. This instrument is executed by, and shall be binding upon Biogen, its
successors and assigns, for the uses and purposes above set forth and referred
to, effective as of the date hereof.
A-1
<PAGE> 11
3.Terms used herein shall have the same meaning that such terms have when
used in the Biogen Amendment. In the event of any inconsistency between the
provisions hereof and the provisions of the Biogen Amendment, the provisions of
the Biogen Amendment shall be controlling. The representation and warranties and
other terms and conditions of the Biogen Amendment shall be incorporated in and
shall survive execution and delivery of this Assignment of Patent Rights.
4. This Assignment of Patent Rights shall be governed by and construed and
enforced in accordance with the laws of the state of New Jersey.
IN WITNESS WHEREOF, Biogen and Schering have caused this Assignment of
Patent Rights to be signed by their respective authorized officers as an
instrument under seal, on the day and year first above written.
SCHERING CORPORATION
By:
-----------------------------------
Title:
BIOGEN, INC.
By:
-----------------------------------
Title:
A-2
<PAGE> 12
SCHEDULE A
ASSIGNED PATENT RIGHTS
"Assigned Patent Rights" shall mean the patent application designated as
U.S. Serial No. 471,301 filed March 2, 1983.
A-3
